TR201818754T4 - Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri - Google Patents

Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri Download PDF

Info

Publication number
TR201818754T4
TR201818754T4 TR2018/18754T TR201818754T TR201818754T4 TR 201818754 T4 TR201818754 T4 TR 201818754T4 TR 2018/18754 T TR2018/18754 T TR 2018/18754T TR 201818754 T TR201818754 T TR 201818754T TR 201818754 T4 TR201818754 T4 TR 201818754T4
Authority
TR
Turkey
Prior art keywords
brimonidine
preservatives
timolol
solutions
timolol solutions
Prior art date
Application number
TR2018/18754T
Other languages
English (en)
Inventor
LIKITLERSUANG Sukhon
F Kelly William
P Parashar Ajay
P Pujara Chetan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201818754(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TR201818754T4 publication Critical patent/TR201818754T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş intraoküler basıncı düşürme ve glokom tedavisi için koruyucu içermeyen brimonidin ve timolol çözeltilerine yöneliktir.
TR2018/18754T 2010-07-29 2011-07-28 Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri TR201818754T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36868110P 2010-07-29 2010-07-29

Publications (1)

Publication Number Publication Date
TR201818754T4 true TR201818754T4 (tr) 2019-01-21

Family

ID=44504227

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/18754T TR201818754T4 (tr) 2010-07-29 2011-07-28 Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri

Country Status (12)

Country Link
US (3) US10213431B2 (tr)
EP (2) EP3434257A1 (tr)
AU (1) AU2011282683B2 (tr)
CA (1) CA2807084C (tr)
DK (1) DK2598119T3 (tr)
ES (1) ES2709180T3 (tr)
HU (1) HUE040283T2 (tr)
PL (1) PL2598119T3 (tr)
PT (1) PT2598119T (tr)
SI (1) SI2598119T1 (tr)
TR (1) TR201818754T4 (tr)
WO (1) WO2012016000A2 (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
GR1008330B (el) * 2013-10-17 2014-10-20 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση εχoν βελτιωμενες φυσικες ιδιοτητες και ογκο σταγονας
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
EP4420726A3 (en) * 2015-03-19 2024-11-13 Allergan, Inc. Fixed dose combination of bromonidine and timolol
HK1245651A1 (en) 2015-06-05 2018-08-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
IL260290B2 (en) 2015-12-30 2023-11-01 Corium Inc Systems and methods for long-term percutaneous administration
US11541018B2 (en) * 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
JP7153010B2 (ja) 2016-07-27 2022-10-13 コリウム， インコーポレイテッド 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
CA3086163A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4195085A (en) 1975-09-26 1980-03-25 Merck & Co., Inc. Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
JP4874795B2 (ja) * 2003-08-22 2012-02-15 ヴィスタ サイエンティフィック エルエルシー キャリヤ
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
PE20121468A1 (es) 2009-12-22 2012-10-28 Allergan Inc Combinacion triple para reduccion de presion intraocular

Also Published As

Publication number Publication date
HUE040283T2 (hu) 2019-02-28
EP3434257A1 (en) 2019-01-30
WO2012016000A2 (en) 2012-02-02
US20140148456A1 (en) 2014-05-29
PT2598119T (pt) 2018-12-17
US10792288B2 (en) 2020-10-06
AU2011282683A1 (en) 2013-03-07
AU2011282683B2 (en) 2016-12-22
CA2807084C (en) 2018-05-22
ES2709180T3 (es) 2019-04-15
SI2598119T1 (sl) 2019-02-28
US10213431B2 (en) 2019-02-26
WO2012016000A3 (en) 2012-03-15
EP2598119A2 (en) 2013-06-05
PL2598119T3 (pl) 2019-03-29
US20190307759A1 (en) 2019-10-10
EP2598119B1 (en) 2018-09-19
CA2807084A1 (en) 2012-02-02
US20210228587A1 (en) 2021-07-29
DK2598119T3 (en) 2019-01-07

Similar Documents

Publication Publication Date Title
TR201818754T4 (tr) Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri
WO2012015998A3 (en) Preservative free bimatoprost and timolol solutions
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
TR201905683T4 (tr) Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY171920A (en) Prevention and treatment of ocular conditions
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201500362A1 (ru) Ингибиторы rho-киназы
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
EA201390198A1 (ru) Гетероциклическое соединение
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
EA201590301A1 (ru) Композиции и способы уменьшения содержания алкоголя в крови
HK1199261A1 (en) Methods for treatment of diseases
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201301332A1 (ru) ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
WO2012015996A3 (en) Preservative free bimatoprost solutions
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
HK1199201A1 (en) Antimicrobial peptides for treatment of infectious diseases
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями
CA2893036C (en) Uses of bacopa monnieri extract
EA201591185A1 (ru) Применение пидотимода для лечения псориаза
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.